Advancing Medicine through Innovation
We are pushing the boundaries to improve the quality of life for cancer patients!
Advancing Medicine through Innovation
We are pushing the boundaries to improve the quality of life for cancer patients!
About Us
Improve Quality of Life (QofL) of Cancer Patients
MyeloShield prevents chemotherapy and radiotherapy induced myelosuppression for >50% of patients receiving chemotherapy, radiotherapy or their combination regimens.
Optimize Chemotherapy
Myelosuppression is a common dose limiting adverse effect, often leading to dose reduction, delay or discontinuation. The reduced relative dose intensity impairs the clinical outcome.